Literature DB >> 10891490

CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily.

A G Eliopoulos1, C Davies, P G Knox, N J Gallagher, S C Afford, D H Adams, L S Young.   

Abstract

CD40, a tumor necrosis factor (TNF) receptor (TNFR) family member, conveys signals regulating diverse cellular responses, ranging from proliferation and differentiation to growth suppression and cell death. The ability of CD40 to mediate apoptosis in carcinoma cells is intriguing given the fact that the CD40 cytoplasmic C terminus lacks a death domain homology with the cytotoxic members of the TNFR superfamily, such as Fas, TNFR1, and TNF-related apoptosis-inducing ligand (TRAIL) receptors. In this study, we have probed the mechanism by which CD40 transduces death signals. Using a trimeric recombinant soluble CD40 ligand to activate CD40, we have found that this phenomenon critically depends on the membrane proximal domain (amino acids 216 to 239) but not the TNFR-associated factor-interacting PXQXT motif in the CD40 cytoplasmic tail. CD40-mediated cytotoxicity is blocked by caspase inhibitors, such as zVAD-fmk and crmA, and involves activation of caspase 8 and caspase 3. Interestingly, CD40 ligation was found to induce functional Fas ligand, TRAIL (Apo-2L) and TNF in apoptosis-susceptible carcinoma cells and to up-regulate expression of Fas. These findings identify a novel proapoptotic mechanism which is induced by CD40 in carcinoma cells and depends on the endogenous production of cytotoxic cytokines and autocrine or paracrine induction of cell death.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891490      PMCID: PMC86001          DOI: 10.1128/MCB.20.15.5503-5515.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  75 in total

1.  Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154).

Authors:  A E Morris; R L Remmele; R Klinke; B M Macduff; W C Fanslow; R J Armitage
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

Review 2.  The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death.

Authors:  C A Smith; T Farrah; R G Goodwin
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

3.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.

Authors:  C Y Wang; M W Mayo; R G Korneluk; D V Goeddel; A S Baldwin
Journal:  Science       Date:  1998-09-11       Impact factor: 47.728

4.  Inhibition of Fas-induced apoptosis by Bcl-2.

Authors:  A Kawahara; T Kobayashi; S Nagata
Journal:  Oncogene       Date:  1998-11-19       Impact factor: 9.867

Review 5.  CD40 ligand and its role in X-linked hyper-IgM syndrome.

Authors:  R E Callard; R J Armitage; W C Fanslow; M K Spriggs
Journal:  Immunol Today       Date:  1993-11

6.  Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand.

Authors:  M P Baker; A G Eliopoulos; L S Young; R J Armitage; C D Gregory; J Gordon
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

Review 7.  CD40 and epithelial cells: across the great divide.

Authors:  L S Young; A G Eliopoulos; N J Gallagher; C W Dawson
Journal:  Immunol Today       Date:  1998-11

8.  Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells.

Authors:  M G Gilligan; P Knox; S Weedon; R Barton; D J Kerr; P Searle; L S Young
Journal:  Gene Ther       Date:  1998-07       Impact factor: 5.250

9.  Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells.

Authors:  M J Martínez-Lorenzo; M A Alava; S Gamen; K J Kim; A Chuntharapai; A Piñeiro; J Naval; A Anel
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

10.  Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2.

Authors:  C L Ren; T Morio; S M Fu; R S Geha
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  43 in total

Review 1.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 2.  Promising therapeutics of gastrointestinal cancers in clinical trials.

Authors:  Lingling Du; Zheng Che; Andrea Wang-Gillam
Journal:  J Gastrointest Oncol       Date:  2017-06

3.  Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents.

Authors:  Jonathan M Weiss; Robert H Wiltout
Journal:  Oncoimmunology       Date:  2014-08-03       Impact factor: 8.110

4.  Differential induction of nuclear factor-kappaB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation.

Authors:  Jalal Ahmed-Choudhury; Clare L Russell; Satinder Randhawa; Lawrence S Young; David H Adams; Simon C Afford; Jalal Ahmed Choudhury
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

5.  Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.

Authors:  Rhea N Coler; Thomas Hudson; Sean Hughes; Po-Wei D Huang; Elyse A Beebe; Mark T Orr
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

6.  Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.

Authors:  Sadia Zafar; Suvi Parviainen; Mikko Siurala; Otto Hemminki; Riikka Havunen; Siri Tähtinen; Simona Bramante; Lotta Vassilev; Hongjie Wang; Andre Lieber; Silvio Hemmi; Tanja de Gruijl; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

7.  CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.

Authors:  Jonathan M Weiss; W Gregory Alvord; Octavio A Quiñones; Jimmy K Stauffer; Robert H Wiltrout
Journal:  Hum Immunol       Date:  2014-05-04       Impact factor: 2.850

Review 8.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

9.  CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.

Authors:  Taha Elmetwali; Peter F Searle; Iain McNeish; Lawrence S Young; Daniel H Palmer
Journal:  Mol Cancer       Date:  2010-03-08       Impact factor: 27.401

10.  Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand.

Authors:  Elizabeth H Humphreys; Kevin T Williams; David H Adams; Simon C Afford
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.